B&K Corp eyes IPO to keep its slow-developing drugs alive
The company focuses on wound-healing PDGF drugs and its core product, Pro-101-2, isn’t expected to enter Phase 3 clinical trials for at least three more years Key Takeaways: B&K lost…
Jiangsu Recbio Shoots to Become Hong Kong’s First HPV Vaccine Stock
The vaccine producer is making a second attempt to list in Hong Kong, as its core HPV vaccine undergoes Phase 3 clinical trials Key takeaways: Jiangsu Recbio has filed a…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
With no cure in sight, drugs firm LianBio begins exit strategy
LIAN.US
